Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand.
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Bone remodelling and bone loss are controlled by a balance between the tumour necrosis factor family molecule osteoprotegerin ligand (OPGL) and its decoy receptor osteoprotegerin (OPG). In addition, OPGL regulates lymph node organogenesis, lymphocyte development and interactions between T cells and dendritic cells in the immune system. The OPGL receptor, RANK, is expressed on chondrocytes, osteoclast precursors and mature osteoclasts. OPGL expression in T cells is induced by antigen receptor engagement, which suggests that activated T cells may influence bone metabolism through OPGL and RANK. Here we report that activated T cells can directly trigger osteoclastogenesis through OPGL. Systemic activation of T cells in vivo leads to an OPGL-mediated increase in osteoclastogenesis and bone loss. In a T-cell-dependent model of rat adjuvant arthritis characterized by severe joint inflammation, bone and cartilage destruction and crippling, blocking of OPGL through osteoprotegerin treatment at the onset of disease prevents bone and cartilage destruction but not inflammation. These results show that both systemic and local T-cell activation can lead to OPGL production and subsequent bone loss, and they provide a novel paradigm for T cells as regulators of bone physiology.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“RANKL is produced by numerous cell types including cells of the osteoblast lineage (46,47) and activated T cells (42,48,49).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [49]
In the citing paper
“T Cells express both soluble and membrane-bound forms of RANKL (49,50), and both forms are implicated in focal bone erosions associated with inflammatory arthritis (26,49).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [49]
In the citing paper
“Within the developed immune system, RANKL is expressed by T cells (42), RANK is expressed by dendritic cells (49), and OPG is expressed by B lymphocytes and dendritic cells (4,70).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [49]
In the citing paper
“However, RANK and RANKL knockout mice had normal Peyer's patches and intact splenic architecture (49,62), indicating that the development of lymph nodes and secondary lymphoid organs can be differentially regulated.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [49]
In the citing paper
“RANKL inhibition via recombinant OPG treatment also results in marked suppression of bone erosions and osteoclasts in several rodent models, including adjuvant arthritis (26,49,177,232,233), collagen-induced arthritis (26,181,233), and TNF-mediated arthritis (136, 234).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [49]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Self-citationOsteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
Self-citationOPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature · doi:10.1038/16852 · Cited by 3,351 · cited 1×
“We show that: (1) p66 is serine phosphorylated upon treatment with hydrogen peroxide (H2O2) or irradiation with ultraviolet light; (2) ablation of p66 enhances cellular resistance to apoptosis induced by H2O2 or ultraviolet light; (3) a serinephosphorylation defective mutant of p66 cannot restore the normal stress res…”
BackgroundSelf-citationRAG-1-deficient mice have no mature B and T lymphocytes
Mombaerts, P., Iacomini, J., Johnson, R. S., Herrup, K., Tonegawa, S., & Papaioannou, V. E. (1992) · Cell · doi:10.1016/0092-8674(92)90030-g · Cited by 2,931
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Self-citationROLE OF CYTOKINES IN RHEUMATOID ARTHRITIS
Feldmann, M., Brennan, F. M., & Maini, R. N. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.397 · Cited by 2,514
A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.
Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M. C., DuBose, R. F., Cosman, D., & Galibert, L. (1997) · Nature · doi:10.1038/36593 · Cited by 2,290
Kotake, S., Udagawa, N., Takahashi, N., Matsuzaki, K., Itoh, K., Ishiyama, S., Saito, S., Inoue, K., Kamatani, N., Gillespie, M. T., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5703 · Cited by 1,696
Hsu, H., Lacey, D. L., Dunstan, C. R., Solovyev, I., Colombero, A., Timms, E., Tan, H.-L., Elliott, G., Kelley, M. J., Sarosi, I., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3540 · Cited by 1,636
Self-citationWong, B. R., Rho, J., Arron, J., Robinson, E., Orlinick, J., Chao, M., Kalachikov, S., Cayani, E., Bartlett, F. S., Frankel, W. N., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.40.25190 · Cited by 1,042
Cited by
Items 901–1,000 of 1,007
Effect of bisphosphonates treatment on cytokine imbalance between TH17 and Treg in osteoporosis
Talaat, R. M., Sidek, A., Mosalem, A., & Kholief, A. (2015) · Inflammopharmacology · doi:10.1007/s10787-015-0233-4 · Cited by 37
Titanium uptake, induction of RANK‐L expression, and enhanced proliferation of human T‐lymphocytes
Cadosch, D., Sutanto, M., Chan, E., Mhawi, A., Gautschi, O. P., von Katterfeld, B., Simmen, H., & Filgueira, L. (2009) · Journal of Orthopaedic Research® · doi:10.1002/jor.21013 · Cited by 36
Grassi, F., Cattini, L., Gambari, L., Manferdini, C., Piacentini, A., Gabusi, E., Facchini, A., & Lisignoli, G. (2013) · Journal of Tissue Engineering and Regenerative Medicine · doi:10.1002/term.1727 · Cited by 38
“Lymphocytes are critical regulators of physiological bone turnover and peak bone mass (Li et al., 2007); in pathological conditions, they are the essential source of the inflammatory cytokines which induce bone erosion (Kong et al., 1999; Weitzmann and Pacifici, 2007).”
BackgroundPiperine alleviates osteoclast formation through the p38/c‐ F os/ NFAT c1 signaling axis
Deepak, V., Kruger, M. C., Joubert, A. M., & Coetzee, M. (2015) · BioFactors · doi:10.1002/biof.1241 · Cited by 46
Imbalanced expression of RANKL and osteoprotegerin mRNA in pannus tissue of rheumatoid arthritis.
Ainola, M., Mandelin, J. M., Liljeström, M., Konttinen, Y. T., & Salo, J. (2008) · PubMed · Cited by 40
Schrum, L. W., Bost, K. L., Hudson, M. C., & Marriott, I. (2003) · Bone · doi:10.1016/s8756-3282(03)00265-5 · Cited by 36
“Infiltrating T lymphocytes have been found in a variety of bone and joint diseases [6–9] and are thought to play roles in either protective immune responses or the exacerbation of inflammatory bone destruction.”
BackgroundExpression of Matrix-Degrading Cysteine Proteinase Cathepsin K in Cholesteatoma
Hansen, T., Unger, R. E., Gaumann, A. K. A., Hundorf, I., Maurer, J., Kirkpatrick, C. J., & Kriegsmann, J. (2001) · Modern Pathology · doi:10.1038/modpathol.3880465 · Cited by 36
Jarry, C. R., Duarte, P. M., Freitas, F. F., de Macedo, C. G., Clemente‐Napimoga, J. T., Saba‐Chujfi, E., Passador‐Santos, F., de Araújo, V. C., & Napimoga, M. H. (2013) · Human Immunology · doi:10.1016/j.humimm.2013.04.013 · Cited by 36
Fakruddin, J. M., & Laurence, J. (2004) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2004.02568.x · Cited by 41
Grčević, D., Lukic, I., Kovačić, N., Ivčević, S., Katavić, V., & Marušić, A. (2006) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2006.03181.x · Cited by 39
Inhibition of antigen presentation and T cell costimulation blocks PTH‐induced bone loss
Bedi, B., Li, J., Grassi, F., Tawfeek, H. A. W., Weitzmann, M. N., & Pacifici, R. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05216.x · Cited by 37
Self-citationUeda, Y., Inaba, M., Takada, K., Fukui, J., Sakaguchi, Y., Tsuda, M., Omae, M., Kushida, T., Iida, H., & Ikehara, S. (2007) · Stem Cells · doi:10.1634/stemcells.2006-0811 · Cited by 36
T cells participate in bone remodeling during the rapid palatal expansion
Li, J., Yu, T., Yan, H., Qiao, Y., Wang, L., Zhang, T., Li, Q., Zhou, Y., & Liu, D. (2020) · The FASEB Journal · doi:10.1096/fj.202001078r · Cited by 35
Self-citationDiversity of NF-κB signalling and inflammatory heterogeneity in Rheumatic Autoimmune Disease
Manou-Stathopoulou, S., & Lewis, M. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2022.101649 · Cited by 36
Antisense oligonucleotide targeting TNF‐α can suppress co‐cr‐mo particle‐induced osteolysis
Dong, L., Wang, R., Zhu, Y., Wang, C., Diao, H., Zhang, C., Zhao, J., & Zhang, J. (2008) · Journal of Orthopaedic Research® · doi:10.1002/jor.20607 · Cited by 35
“Moreover, antisense oligonucleotide neutralizes more than soluble TNF-a.”
BackgroundInfluentialActivated human T cells express alternative mRNA transcripts encoding a secreted form of RANKL
Walsh, N. C., Alexander, K. A., Manning, C. A., Karmakar, S., Wang, J. F., Weyand, C. M., Pettit, A. R., & Gravallese, E. M. (2013) · Genes and Immunity · doi:10.1038/gene.2013.29 · Cited by 41
Mucci, J. M., Scian, R., Francesco, P. N. D., García, F. S., Ceci, R., Fossati, C. A., Delpino, M. V., & Rozenfeld, P. A. (2012) · Gene · doi:10.1016/j.gene.2012.07.071 · Cited by 35
Activated γδ T cells inhibit osteoclast differentiation and resorptive activity in vitro
Pappalardo, A., & Thompson, K. (2013) · Clinical & Experimental Immunology · doi:10.1111/cei.12165 · Cited by 38
RANKL is a therapeutic target of bone destruction in rheumatoid arthritis
Tanaka, S. (2019) · F1000Research · doi:10.12688/f1000research.17296.1 · Cited by 39
Ogawa, S., Kitaura, H., Kishikawa, A., Qi, J., Shen, W.-R., Ohori, F., Noguchi, T., Marahleh, A., Nara, Y., Ochi, Y., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0223989 · Cited by 41
Tian, H., Chen, F., Wang, Y., Liu, Y., Ma, G., Zhao, Y., Ma, Y., Tian, T., Ma, R., Yu, Y., et al. (2022) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17238 · Cited by 35
Anti‐RANKL therapy for inflammatory bone disorders: Mechanisms and potential clinical applications
Anandarajah, A., & Schwarz, E. M. (2005) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20674 · Cited by 37
“Other studies have provided compelling evidence that activated T cells from the RA synovium and synovial fibroblasts produce RANKL [Kong et al., 1999; Gravallese et al., 2000; Takayanagi et al., 2000].”
BackgroundNormal human primary CD4+ T lymphocytes synthesize and release functional osteoprotegerin in vitro
Chakravarti, A., Marceau, A.-A., Flamand, L., & Poubelle, P. E. (2007) · Laboratory Investigation · doi:10.1038/labinvest.3700701 · Cited by 37
“5 OPG treatment of a T-cell-dependent arthritis in rats prevents bone and cartilage destruction by blocking the effects of RANKL produced by activated T lymphocytes”
BackgroundKim, J. H., Kim, K., Youn, B. U., Jin, H. M., & Kim, N. (2010) · Cellular Signalling · doi:10.1016/j.cellsig.2010.05.001 · Cited by 39
Significance of the fibrous stroma in bone invasion by human gingival squamous cell carcinomas
Ishikuro, M., Sakamoto, K., Kayamori, K., Akashi, T., Kanda, H., Izumo, T., & Yamaguchi, A. (2008) · Bone · doi:10.1016/j.bone.2008.05.014 · Cited by 35
“[9] reported that activated T cells regulate osteoclastogenesis by synthesizing RANKL in adjuvant arthritis.”
BackgroundKato, G., Shimizu, Y., Arai, Y., Suzuki, N., Sugamori, Y., Maeda, M., Takahashi, M., Tamura, Y., Wakabayashi, N., Murali, R., et al. (2015) · Arthritis Research & Therapy · doi:10.1186/s13075-015-0753-8 · Cited by 36
Young, N., Mikhalkevich, N., Yan, Y., Chen, D., & Zheng, W.-P. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.12.8287 · Cited by 39
“For example, activated T cells not only express RANKL themselves (13), but also secrete IL-17 to upregulate RANKL expression on osteoblasts (6) to induce osteoclastogenesis.”
BackgroundAn Increased Risk of Osteoporosis during Acquired Immunodeficiency Syndrome
Annapoorna, N., Rao, G. V., Reddy, N. S., Rambabu, P., & Rao, K. R. S. S. (2004) · International Journal of Medical Sciences · doi:10.7150/ijms.1.152 · Cited by 35
“The hypothesis that the systemic activation of T cells in vivo leads to an osteoprotegerin ligandmediated increase in osteoclastogenesis and bone loss [64].”
BackgroundOsteoclasts are essential for TNF-α–mediated joint destruction
Redlich, K., Hayer, S., Ricci, R., David, J., Tohidast-Akrad, M., Kollias, G. A., Steiner, G. E., Smolen, J. S., Wagner, E. F., & Schett, G. A. (2002) · Journal of Clinical Investigation · doi:10.1172/jci200215582 · Cited by 35
Sugiyama, T. (2001) · Journal of Bone and Mineral Metabolism · doi:10.1007/s007740170046 · Cited by 35
Novel and Selective Small Molecule Stimulators of Osteoprotegerin Expression Inhibit Bone Resorption
Onyia, J. E., Galvin, R. J. S., Li, Y., Halladay, D., Miles, R. R., Yang, X., Fuson, T. R., Cain, R. L., Zeng, Q. Q., Chandrasekhar, S., et al. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.057893 · Cited by 37
“Previous studies have demonstrated that exogenously administered OPG inhibits osteoclastogenesis and bone resorption in experimental models of arthritis and tumor metastasis (Kong et al., 1999a; Capparelli et al., 2000).”
BackgroundResultInfluentialThe Role of Calmodulin in the Regulation of Osteoclastogenesis
Zhang, L., Feng, X., & McDonald, J. M. (2003) · Endocrinology · doi:10.1210/en.2003-0147 · Cited by 35
Innate immune response to bone fracture healing
Burgan, J., Rahmati, M., Lee, M., & Saiz, A. M. (2024) · Bone · doi:10.1016/j.bone.2024.117327 · Cited by 38
Brief Report: Involvement of TNFRSF11A Molecular Defects in Autoinflammatory Disorders
Jéru, I., Cochet, E., Duquesnoy, P., Hentgen, V., Copin, B., Mitjavila‐Garcia, M. T., Sheykholeslami, S., Borgne, G. L., Moal, F., Malan, V., et al. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38727 · Cited by 37
Inflammatory signaling induced bone loss
Goldring, S. R. (2015) · Bone · doi:10.1016/j.bone.2015.05.024 · Cited by 34
Oestrogen deficiency modulates particle-induced osteolysis
Nich, C., Langlois, J., Marchadier, A., Vidal, C., Cohen-Solal, M. E., Petite, H., & Hamadouche, M. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3381 · Cited by 35
IKKβ as a target for treatment of inflammation induced bone loss
Ruocco, M. G., & Karin, M. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.042721 · Cited by 35
Osteoporosis in psoriatic arthritis: Is there any?
Grazio, S., Cvijetić, S., Vlak, T., Grubišić, F., Matijević, V., Nemčić, T., Punda, M., & Kusić, Z. (2011) · Wiener klinische Wochenschrift · doi:10.1007/s00508-011-0095-8 · Cited by 34
Okahashi, N., Sakurai, A., Nakagawa, I., Fujiwara, T., Kawabata, S., Amano, A., & Hamada, S. (2003) · Infection and Immunity · doi:10.1128/iai.71.2.948-955.2003 · Cited by 34
“The role of RANKL on activated osteoblasts in osteoclastogenesis is widely recognized, whereas the significance of RANKL on T cells is controversial because activated T cells produce gamma interferon, which strongly inhibits osteoclastogenesis (17, 28).”
BackgroundInfluentialInflammatory Bowel Disease: Effects on Bone and Mechanisms
Sylvester, F. A. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-66653-2_7 · Cited by 35
Periodontal ligament stem cells in tissue remodeling: from mechanical forces to inflammatory signals
Zhao, Z., Chen, L., Zhu, S., Yu, H., Chen, Y., Song, J., Liu, Y., & He, D. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04777-6 · Cited by 41
“T cells, as key mediators of adaptive immunity, critically regulate bone remodeling processes during OTM [27, 28].”
Novel targets in bone and cartilage
Beyer, C., & Schett, G. A. (2010) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2010.03.001 · Cited by 35
Chiechi, A., Novello, C., Magagnoli, G., Petricoin, E. F., Deng, J., Benassi, M. S., Picci, P., Vaisman, I. I., Espina, V. A., & Liotta, L. A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3416 · Cited by 36
Immunomodulatory effect of vitamin K2: Implications for bone health
Myneni, V. D., & Mezey, É. (2018) · Oral Diseases · doi:10.1111/odi.12759 · Cited by 34
Meng, B., Wu, D., Cheng, Y., Huang, P., Liu, Y., Gan, L., Liu, C., & Cao, Y. (2020) · Scandinavian Journal of Immunology · doi:10.1111/sji.12874 · Cited by 38
Tseng, W., Graham, L. S., Geng, Y., Reddy, A., Lu, J., Effros, R. B., Demer, L. L., & Tintut, Y. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.117366 · Cited by 34
Denosumab: an investigational drug for the management of postmenopausal osteoporosis
Lewiecki, M. E. (2008) · Biologics · doi:10.2147/btt.s2082 · Cited by 37
Zhu, X. Y., Gao, J., Landao‐Bassonga, E., Pavlos, N. J., Qin, A., Steer, J. H., Zheng, M., Dong, Y., & Cheng, T. S. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.02.013 · Cited by 33
Strength, toughness, and reliability of a porous glass/biopolymer composite scaffold
Fu, Q., Jia, W., Lau, G. Y., & Tomsia, A. P. (2017) · Journal of Biomedical Materials Research Part B Applied Biomaterials · doi:10.1002/jbm.b.33924 · Cited by 34
Rutsch, F., & Terkeltaub, R. A. (2004) · Joint Bone Spine · doi:10.1016/j.jbspin.2004.05.014 · Cited by 38
Narducci, P., Bareggi, R., & Nicolin, V. (2009) · Acta Histochemica · doi:10.1016/j.acthis.2009.10.003 · Cited by 37
“The phenotype of RANKL-deficient mice is characterized by a lack of lymph nodes and hypoplasia of the thymus and Peyer’s patches, indicating that RANKL is essential for normal embryological development of lymphoid tissue (Dougall et al., 1999; Kong et al., 1999a, 1999b) in healthy subjects.”
BackgroundInfluentialMancini, L., Paul-Clark, M. J., Rosignoli, G., Hannon, R., Martin, J. E., Macintyre, I., & Perretti, M. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.060830 · Cited by 32
Fu, Y., Li, G., Zhang, X., Xing, G., Hu, X., Yang, L., & Li, D. (2015) · Nutrients · doi:10.3390/nu7010625 · Cited by 37
Galectin-3 in bone tumor microenvironment: a beacon for individual skeletal metastasis management
Nakajima, K., Kho, D. H., Yanagawa, T., Zimel, M. N., Heath, E. I., Hogan, V. A., & Raz, A. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9622-4 · Cited by 33
Anti-mouse RANKL Antibodies Inhibit Alveolar Bone Destruction in Periodontitis Model Mice
Kuritani, M., Sakai, N., Karakawa, A., Isawa, M., Chatani, M., Negishi‐Koga, T., Funatsu, T., & Takami, M. (2018) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b18-00026 · Cited by 34
Emerging anti-osteoclast therapy for rheumatoid arthritis
Tanaka, S. (2018) · Journal of Orthopaedic Science · doi:10.1016/j.jos.2018.06.001 · Cited by 32
The osteoclast, a target cell for microorganisms
Raynaud‐Messina, B., Vérollet, C., & Maridonneau‐Parini, I. (2019) · Bone · doi:10.1016/j.bone.2019.06.023 · Cited by 36
Xu, X., Shu, G., Wang, X., Qi, J., Jin, F., Shen, Q., Ying, X., Ji, J., & Du, Y. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.04.047 · Cited by 32
The Unexpected Link Between Osteoclasts and the Immune System
Takayanagi, H. (2009) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-1050-9_7 · Cited by 38
Circulating RANKL is inversely related to RANKL mRNA levels in bone in osteoarthritic males
Findlay, D. M., Chehade, M. J., Tsangari, H., Neale, S. D., Hay, S. J., Hopwood, B., Pannach, S., O’Loughlin, P. D., & Fazzalari, N. L. (2008) · Arthritis Research & Therapy · doi:10.1186/ar2348 · Cited by 39
Osteoporosis and Fracture Risk Associated with HIV Infection and Treatment
Compston, J. E. (2014) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2014.05.001 · Cited by 32
The unbearable lightness of bone marrow homeostasis
Agas, D., Marchetti, L., Douni, E. K., & Sabbieti, M. G. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.12.004 · Cited by 33
Denosumab for the treatment of bone metastases in advanced breast cancer
Casas, A., Llombart‐Cussac, A., & Martín, M. (2013) · The Breast · doi:10.1016/j.breast.2013.05.007 · Cited by 34
Valverde, P., Kawai, T., & Taubman, M. A. (2005) · Journal of Dental Research · doi:10.1177/154405910508400603 · Cited by 33
“Since RANKL is expressed by T-cells following TCR stimulation (Kong et al., 1999b; Theill et al., 2002), and its transcriptional up-regulation is partly Ca2+-dependent (Kong et al., 1999b; Wang et al., 2002), down-regulation of Ca2+ signaling in T-lymphocytes would be expected to decrease RANKL expression and RANKL-me…”
BackgroundResultInfluentialTWEAK Promotes Osteoclastogenesis in Rheumatoid Arthritis
Park, J., Kwok, S., Lim, M.-A., Oh, H.-J., Kim, E., Jhun, J., Ju, J. H., Park, K.-S., Park, Y., Park, S., et al. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.05.027 · Cited by 32
Alterations in the phenotype and function of immune cells in ovariectomy-induced osteopenic mice
García‐Pérez, M. Á., Noguera, I., Hermenegildo, C., Martínez‐Romero, A., Tarín, J. J., & Cano, A. (2006) · Human Reproduction · doi:10.1093/humrep/dei413 · Cited by 31
“The increase in RANKL T cells could participate in the increased osteoclastogenesis after ovariectomy, as has been described (Kong et al., 1999).”
BackgroundHirayama, T., Dai, S., Abbas, S., Yamanaka, Y., & Abu‐Amer, Y. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21286 · Cited by 37
Halladay, D., Miles, R. R., Thirunavukkarasu, K., Chandrasekhar, S., Martin, T. J., & Onyia, J. E. (2001) · Journal of Cellular Biochemistry · doi:10.1002/jcb.1273 · Cited by 36
“Received 9 July 2001; Accepted 12 July 2001 metastasis, periodontal disease, and adjuvant arthritis [Akatsu et al., 1998; Yamamoto et al., 1998; Kong et al., 1999; Morony et al., 1999; Capparelli et al., 2000; Honore et al., 2000; Min et al., 2000; Teng et al., 2000].”
BackgroundGuillonneau, C., Louvet, C., Renaudin, K., Heslan, J., Heslan, M., Tesson, L., Vignes, C., Guillot, C., Choi, Y., Turka, L. A., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.3.1619 · Cited by 33
Yano, K., Nakagawa, N., Yasuda, H., Tsuda, E., & Higashio, K. (2001) · Journal of Bone and Mineral Metabolism · doi:10.1007/s007740170006 · Cited by 33
Bone Involvement in Rheumatoid Arthritis and Spondyloartritis: An Updated Review
Orsini, F., Crotti, C., Cincinelli, G., Taranto, R. D., Amati, A., Ferrito, M., VARENNA, M., & Caporali, R. F. (2023) · Biology · doi:10.3390/biology12101320 · Cited by 32
Complement C1q production by osteoclasts and its regulation of osteoclast development
Teo, B. H. D., Bobryshev, Y. V., Teh, B. K., Wong, S. H., & Lu, J. (2012) · Biochemical Journal · doi:10.1042/bj20120888 · Cited by 35
Iwamoto, Y., Nishikawa, K., Imai, R., Furuya, M., Uenaka, M., Ohta, Y., Morihana, T., Itoi‐Ochi, S., Penninger, J. M., Katayama, I., et al. (2016) · Molecular and Cellular Biology · doi:10.1128/mcb.01028-15 · Cited by 41
Self-citationWu, L.-Q., Li, Y., Li, Y.-Y., Xu, S.-H., Yang, Z.-Y., Lin, Z., & Li, J. (2016) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2015.168 · Cited by 33
“Serum TNFα, IL-1β and IL-6 aggravate bone and joint injury in arthritic patients (Kong et al., 1999) and blockage with monoclonal antibodies of pro-inflammatory cytokines, such as adalimumab for TNFα, tocilizumab for IL-6 can reduce swelling and pain in clinical osteoarthritis patients (Weinblatt…”
BackgroundSelf-citationBrucella and Osteoarticular Cell Activation: Partners in Crime
Giambartolomei, G. H., Benítez, P. C. A., & Delpino, M. V. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.00256 · Cited by 34
“…conditions such as estrogen deficiency (Kong et al., 1999; Cenci et al., 2000; Roggia et al., 2001; Kawai et al., 2006) and inflammation (Kong et al., 1999; Kawai et al., 2006) as they become significant sources of RANKL (Kong et al., 1999), TNF-α (Cenci et al., 2000), and IL-17 (Sato…”
BackgroundDenosumab: Current Use in the Treatment of Primary Bone Tumors
Savvidou, O. D., Bolia, I. K., Chloros, G. D., Papanastasiou, J., Koutsouradis, P., & Papagelopoulos, P. J. (2017) · Orthopedics · doi:10.3928/01477447-20170627-04 · Cited by 32
Suppressive Effect of Kanzo-bushi-to, a Kampo Medicine, on Collagen-Induced Arthritis
Ono, Y., Inoue, M., Mizukami, H., & Ogihara, Y. (2004) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.27.1406 · Cited by 31
Pemphigus and Osteoporosis: A Case-Control Study
Wohl, Y., Dreiher, J., & Cohen, A. D. (2010) · Archives of Dermatology · doi:10.1001/archdermatol.2010.257 · Cited by 32
Andersson, M. K., Lundberg, P., Ohlin, A., Perry, M. J., Lie, A., Stark, A., & Lerner, U. H. (2007) · Arthritis Research & Therapy · doi:10.1186/ar2127 · Cited by 31
Tyrovola, J. B., Perrea, D. N., Halazonetis, D. J., Dontas, I. A., Vlachos, I. S., & Makou, M. (2010) · Journal of Oral Science · doi:10.2334/josnusd.52.299 · Cited by 31
“RANKL, together with another very important protein ligand, M-CSF (which binds to its receptor c-fms), is to promote osteoclast formation, fusion, differentiation, activation, and survival, thus enhancing bone resorption (10-19).”
BackgroundResultChronic pediatric inflammatory diseases: Effects on bone
Viswanathan, A., & Sylvester, F. A. (2007) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-007-9070-0 · Cited by 33
Ozaki, Y., Ukai, T., Yamaguchi, M., Yokoyama, M., Haro, E. R. A., Yoshimoto, M., Kaneko, T., Yoshinaga, M., Nakamura, H., Shiraishi, C., et al. (2009) · Bone · doi:10.1016/j.bone.2009.01.375 · Cited by 31
Skeletal deterioration induced by RANKL infusion: a model for high-turnover bone disease
Yuan, Y. Y., Kostenuik, P. J., Ominsky, M. S., Morony, S., Adamu, S., Simionescu, D. T., Basalyga, D. M., Asuncion, F., & Bateman, T. A. (2007) · Osteoporosis International · doi:10.1007/s00198-007-0509-7 · Cited by 33
Self-citationRheumatoid arthritis: inflammation and bone loss
Schett, G. A. (2006) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-005-0244-7 · Cited by 33
Strålberg, F., Kassem, A., Kasprzykowski, F., Abrahamson, M., GRUBB, A. O., Lindholm, C., & Lerner, U. H. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.3a1016-433r · Cited by 38
Zhang, X., Alnaeeli, M., Singh, B., & Teng, Y.-T. A. (2009) · Infection and Immunity · doi:10.1128/iai.01070-08 · Cited by 31
Hikita, A., Kadono, Y., Chikuda, H., Fukuda, A., Wakeyama, H., Yasuda, H., Nakamura, K., Oda, H., Miyazaki, T., & Tanaka, S. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m507000200 · Cited by 31
Qiao, B., Shui, W., Cai, L., Guo, S., & Jiang, D. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s77116 · Cited by 30
Blockade of IL-1 family cytokines in the treatment of rheumatoid arthritis
Wang, K., Luo, H., Liu, L., Gao, H., Song, Y., & Li, D. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1577628 · Cited by 52
“This bioactive cytokine binds IL-1R to amplify NF-κ B/MAPK signaling in osteoclast precursors, driving NFATc1-dependent differentiation and bone resorption (Kong et al., 1999; Roux and Orcel, 2000).”
Wei, J., Jian, W., Gong, Y., & Zeng, R. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3637 · Cited by 36
Cells of the Immune System Orchestrate Changes in Bone Cell Function
Wythe, S. E., Nicolaidou, V., & Horwood, N. J. (2013) · Calcified Tissue International · doi:10.1007/s00223-013-9764-0 · Cited by 37
Hauser, B., Riches, P. L., Gilchrist, T. L., Visconti, M. R., Wilson, J. F., & Ralston, S. H. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-207219 · Cited by 30
The role of osteoprotegerin in arthritis.
Schett, G. A., Redlich, K., & Smolen, J. S. (2003) · Arthritis Research · doi:10.1186/ar990 · Cited by 36
Xiao, Y., Song, J., de Vries, T. J., Fatmawati, C., Parreira, D. B., Langenbach, G. E. J., Bąbała, N., Nolte, M. A., Everts, V. E., & Borst, J. G. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1216082110 · Cited by 35
Functional CD40 Expression Induced following Bacterial Infection of Mouse and Human Osteoblasts
Schrum, L. W., Marriott, I., Butler, B. R., Thomas, E. K., Hudson, M., & Bost, K. L. (2003) · Infection and Immunity · doi:10.1128/iai.71.3.1209-1216.2003 · Cited by 30
Olivier, B. J., Schoenmaker, T., Mebius, R. E., Everts, V., Mulder, C. J., van Nieuwkerk, K. M. J., de Vries, T. J., & van der Merwe, S. W. (2008) · Hepatology · doi:10.1002/hep.21971 · Cited by 31
Wang, B., Jin, H., Shu, B., Mira, R. R., & Chen, D. (2015) · Scientific Reports · doi:10.1038/srep13667 · Cited by 35
Quantitative increase in T regulatory cells enhances bone remodeling in osteogenesis imperfecta
Kang, I.-H., Baliga, U. K., Chatterjee, S., Chakraborty, P., Choi, S., Buchweitz, N., Li, H., Wu, Y., Yao, H., Mehrotra, S., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104818 · Cited by 28
Khajuria, D. K., Reider, I., Kamal, F., Norbury, C. C., & Elbarbary, R. A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1250309 · Cited by 15
Panach, L., Serna, E., Tarín, J. J., Cano, A., & García-Pérez, M. Á. (2017) · Osteoporosis International · doi:10.1007/s00198-017-4061-9 · Cited by 13
Metadata
- Authors
- Kong, Y.-Y., Feige, U., Sarosi, I., Bolon, B., Tafuri, A., Morony, S., Capparelli, C., Li, J., Elliott, R., McCabe, S., Wong, T., Campagnuolo, G., Moran, E., Bogoch, E. R., Van, G., Nguyen, L. T., Ohashi, P. S., Lacey, D. L., Fish, E., Boyle, W. J., & Penninger, J. M.
- Affiliations
- Amgen (Canada) (CA)
- Amgen (United States) (US)
- St. Michael's Hospital (CA)
- University of Toronto (CA)
- ORCID
- Venue
- Nature
- Published
- 1999-11
- Volume
- 402
- Issue
- 6759
- Pages
- 304-309
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1677043489
- Cited by
- 1,856
- References
- 24
- Citations by year
- 2026: 17 · 2025: 33 · 2024: 36 · 2023: 33 · 2022: 25 · 2021: 36 · 2020: 47 · 2019: 43 · 2018: 38 · 2017: 59 · 2016: 64 · 2015: 82 · 2014: 80 · 2013: 85 · 2012: 77
- FWCI
- 26.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Cystic Fibrosis Foundation
- U.S. Public Health Service
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Health Sciences › Medicine › Rheumatology › Osteomyelitis and Bone Disorders Research
- Keywords
- osteoprotegerin ligand, osteoprotegerin, RANK, activated T cells, adjuvant-induced arthritis, bone loss, osteoclastogenesis, joint destruction, cartilage destruction, T cell activation, bone remodeling, osteoclasts
- MeSH terms
- Animals, Arthritis, Experimental, Bone and Bones, Bone Resorption, Carrier Proteins, Cartilage, Cells, Cultured, Glycoproteins, Humans, Lymphocyte Activation, Membrane Glycoproteins, Mice, Inbred C57BL, Rats, Inbred Lew, T-Lymphocytes, Receptors, Tumor Necrosis Factor, Receptors, Cytoplasmic and Nuclear, Coculture Techniques, Mice, Rats, Osteoprotegerin, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.